Can the effects of protein restriction on the progression of renal failure also be achieved by pharmacological means?
A review is given of recent data on the role of cyclo-oxygenase products in mediating glomerular hyperfiltration in renal disease and on the role of prostaglandins in protein-induced glomerular hyperfiltration. The possible beneficial effects of cyclo-oxygenase inhibitors and thromboxane synthetase inhibitors are discussed.
Verberckmoes
R
R
Department of Pathophysiology, K.U. Leuven University Hospital, Belgium.
Van Renterghem
Y
Y
D000818:Animals; D016861:Cyclooxygenase Inhibitors; D004044:Dietary Proteins / Q000008:administration & dosage*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D051379:Mice; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*; D011453:Prostaglandins / Q000502:physiology; D051381:Rats; D012079:Renal Circulation / Q000187:drug effects; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D004044:Dietary Proteins; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D013930:Thromboxane-A Synthase